A study to collect survival data on patients previously enrolled in Abraxane pancreatic cancer study CA046.
A study to collect survival status of CA046 subjects who were know to be alive at the last report of vital status for CA046 - approximate timeframe - end of March, 2013. Once consent is given, on a quarterly basis, information on status will be collected to include: * Vital Status * Date of disease progression * Subsequent anticancer therapy for pancreatic adenocarcinoma
Study Type
OBSERVATIONAL
Enrollment
40
No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
Overall Survival
Number of participants who survive
Time frame: up to 3 years
Disease progression
Date of disease progression and subsequent anticancer therapy for pancreatic adenocarcinoma other than that already recorded for subject while enrolled in CA046
Time frame: up to 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
TGen Clinical Research Services
Scottsdale, Arizona, United States
Mayo Clinic
Scottsdale, Arizona, United States
Pacific Shores Medical Group
Long Beach, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Florida Cancer Specialists
Englewood, Florida, United States
Florida Cancer Specialist
Tavares, Florida, United States
Indiana University
Indianapolis, Indiana, United States
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts, United States
Arena Oncology Associates
Lake Success, New York, United States
UPMC Cancer Pavillion
Pittsburgh, Pennsylvania, United States
...and 29 more locations